Display options
Cite
Navarro NS, Campos MI, Alvarado R, et al. Ertapenem versus ceftriaxone and metronidazole as treatment for complicated intra-abdominal infections. Int J Surg. 2005;3(1):25-34doi: 10.1016/j.ijsu.2005.03.010.
Navarro, N. S., Campos, M. I., Alvarado, R., Quintero, N., Branicki, F. J., Wei, J., Shivaprakash, M., Vrijens, F., Giezek, H., Chan, C. Y., DiNubile, M. J. (2005). Ertapenem versus ceftriaxone and metronidazole as treatment for complicated intra-abdominal infections. International journal of surgery (London, England), 3(1), 25-34. https://doi.org/10.1016/j.ijsu.2005.03.010
Navarro, Narcisco S, et al. "Ertapenem versus ceftriaxone and metronidazole as treatment for complicated intra-abdominal infections." International journal of surgery (London, England) vol. 3,1 (2005): 25-34. doi: https://doi.org/10.1016/j.ijsu.2005.03.010
Navarro NS, Campos MI, Alvarado R, Quintero N, Branicki FJ, Wei J, Shivaprakash M, Vrijens F, Giezek H, Chan CY, DiNubile MJ. Ertapenem versus ceftriaxone and metronidazole as treatment for complicated intra-abdominal infections. Int J Surg. 2005;3(1):25-34. doi: 10.1016/j.ijsu.2005.03.010. PMID: 17462256.
Copy Download .nbib Format: NLM
Share it on

Int J Surg. 2005;3(1):25-34. doi: 10.1016/j.ijsu.2005.03.010.

Ertapenem versus ceftriaxone and metronidazole as treatment for complicated intra-abdominal infections.

International journal of surgery (London, England)

Narcisco S Navarro, Maria I Campos, Ramon Alvarado, Nora Quintero, Frank J Branicki, Junmin Wei, Malathi Shivaprakash, France Vrijens, Hilde Giezek, Christina Y Chan, Mark J DiNubile,

Affiliations

  1. Jose Reyes Memorial Hospital, Manila, Philippines.

PMID: 17462256 DOI: 10.1016/j.ijsu.2005.03.010

Abstract

BACKGROUND: Prompt surgical intervention supplemented by appropriate antimicrobial therapy is usually required for successful treatment of complicated intra-abdominal infections. The objective of this study was to further evaluate the efficacy and safety of ertapenem relative to ceftriaxone/metronidazole as treatment for complicated intra-abdominal infections.

METHODS: Adult patients with intra-abdominal infections requiring surgery were eligible for this open-label randomized trial comparing ertapenem 1 g daily with ceftriaxone 2 g daily plus metronidazole 30 mg/kg/day. The primary efficacy outcome was the clinical response rate in clinically and microbiologically evaluable participants at the test-of-cure (TOC) visit 2 weeks after discontinuation of therapy. All treated patients were included in the safety analysis.

RESULTS: Participant demographics, disease characteristics, and duration of therapy in both treatment groups were generally similar. Escherichia coli was the most commonly isolated baseline pathogen, recovered in 52% of cases in each treatment group. Favorable clinical responses were achieved at TOC in 143 (96.6%) of 148 ertapenem recipients and in 146 (96.7%) of 151 ceftriaxone/metronidazole recipients. The frequencies of drug-related adverse events, most commonly nausea, diarrhea, vomiting, and elevated platelet count, were generally comparable in both treatment arms. Four ertapenem recipients (1.8%) and one ceftriaxone/metronidazole recipient (0.4%) experienced serious drug-related adverse events.

CONCLUSIONS: In this study, ertapenem and ceftriaxone/metronidazole were comparably effective treatments for adult patients with complicated intra-abdominal infections.

Publication Types